Expression of cyclooxygenase-2 in transitional cell carcinoma of the urinary bladder in dogs

American Journal of Veterinary Research

Volumn 61, Issue 5, 2000, Pages 478-481

  Khan, K Nasir M ^a   Knapp, Deborah W ^b   Denicola, Dennis B ^b   Harris, R Keith ^a  

^a PFIZER INC   (United States)

^b PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL TISSUE; ARTICLE; BLADDER CARCINOMA; BLADDER EPITHELIUM; CONTROLLED STUDY; DOG; ENZYME INHIBITION; IMMUNOHISTOCHEMISTRY; METASTASIS; NONHUMAN; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR GROWTH;

ANIMALIA; CANIS FAMILIARIS;

EID: 0034107624     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2000.61.478     Document Type: Article

References (17)

1. Knapp DW, Richardson RC, Chan TCK, et al. Piroxicam therapy in 34 dogs with transitional cell carcinoma of the urinary bladder. J Vet Intern Med 1994;8:273-278.
2. Vane JR, Bakhle YS, Bolting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxical 1998;38:97-120.
3. Needleman P, Isakson PC. The discovery and function of COX-2. J Rheumatol 1997;49(suppl):6-8.
4. Dubois RN, Abramson SB, Crofford L, et al. Cyclooxygenase in biology and disease. FASEB J 1998;12:1063-1073.
5. Khan KNM, Venturini CM, Bunch RT, et al. Interspecies differences in renal localization of cyclooxygenase isoforms: implications in nonsteroidal antiinflaminatory drug-related nephrotoxicity. Toxicol Pathol 1998;26:612-620.
6. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325: 1593-1596.
7. Giovanucci E, Egan KM, Hunter DJ, et al. Aspirin and risk of colorectal cancer in women. N Engl J Med 1995;333:609-614.
8. Reddy BS, Tokumo K, Kulkarni N, et al. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis (Lond) 1992;13:1019-1023.
9. Rao CV, Tokumo K, Rigotty J, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, α-difluoromethylornithine, 16α-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51: 4528-4534.
10. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific COX-2 inhibitor, against colon carcinogenesis. Cancer Res 1998;58:409-412.
11. Knapp DW, Richardson RC, Bottoms GD, et al. Phase I trial of piroxicam in 62 dogs bearing naturally occurring tumors. Cancer Chemother Pharmacol 1992;29:214-218.
12. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313-1316.
13. Park JM, Yang T, Arend LJ, et al. Cyclooxygenase-2 is expressed in bladder during fetal development and stimulated by outlet obstruction. Am J Physiol 1997;273:F538-F544.
14. Sirois J, Richards JS. Purification and characterization of a novel, distinct isoform of prostaglandin endoperoxide synthase induced by human chorionic gonadotropin in granulosa cells of rat preovulatory follicles. J Biol Chem 1992;267:6382-6388.
15. Morham SG, Langenbach R, Loftin CD, et al. Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse. Cell 1995;83:473-482.
16. Simon LS. Actions and toxic effects of the nonsteroidal anti-inflammatory drugs. Curr Opin Rheumatol 1994;6:238-251.
17. Masfferer JL, Zweifel BS, Manning PT, et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is anti-inflammatory and nonulcerogenic. Proc Natl Acad Sci U S A, 1994;91:3228-3232.